Logo
Revs PRO32

Revs PRO32

REVS

Skin Booster
  • Listed by multiple European distributors as CE Certified, indicating conformity with applicable EU/UK cosmetic/medical device regulations for injectable HA Based skin boosters.
  • CPNP Registered as a mesotherapy/skin booster product for injection in the superficial dermis in EU markets (per distributor information).
  • Manufactured in South Korea by Reanzen Co., Ltd. under cosmetic/medical manufacturing quality standards.
  • Non Animal Derived hyaluronic acid formulation aligned with international safety and quality expectations for injectable HA products.
  • Intended for professional use only, in accordance with local regulatory and professional guidelines for injectable aesthetic products.
Hybrid Hyaluronic Acid Skin Booster for Skin Remodelling and Laxity

Description

Revs PRO32 is a stabilised, hybrid hyaluronic acid (HA) skin booster specifically formulated for skin remodelling and the treatment of skin laxity, rather than simply filling lines and wrinkles. Each 2 ml prefilled syringe contains a total of 64 mg of HA, evenly split into 32 mg high molecular weight HA (H-HA) and 32 mg low molecular weight HA (L-HA). This dual-weight, non-BDDE crosslinked formulation allows gradual release of HA into multiple layers of the skin, delivering deep hydration, biorevitalisation and a soft-lifting effect. Revs PRO32 is designed for use in areas affected by laxity such as the malar and submalar regions of the face, but can also be used as a full-face skin booster to improve overall tissue quality, firmness, elasticity, and radiance. It nourishes dermal cells, stimulates collagen and elastin activity, and complements other aesthetic procedures, including dermal fillers. The product is supplied as a sterile single-use 2 ml syringe (needles typically not included) and is intended for administration by trained medical or aesthetic professionals using techniques such as the 5-point/BAP method in the superficial dermis.

Bnefits

  • Hybrid skin booster with 64 mg total hyaluronic acid (32 mg H-HA + 32 mg L-HA) per 2 ml syringe for intensive hydration and tissue remodelling.
  • Targets skin laxity and tissue quality, especially in malar and submalar facial regions, rather than only treating lines and wrinkles.
  • Improves firmness, elasticity and skin tone while providing a subtle soft-lifting, tightening effect.
  • Nourishes dermal cells and stimulates collagen and elastin activity for long-term biorevitalisation.
  • Provides deep, long-lasting hydration to restore plumpness and radiance to dull, dehydrated or ageing skin.
  • Complementary to other aesthetic treatments such as dermal fillers and toxins, enhancing overall rejuvenation protocols.
  • Fragmented HA with high and low molecular weights allows multi-layer hydration and gradual release within the dermis.
  • Smooth, easy injection characteristics that suit 5-point/BAP and mesotherapy techniques for even product distribution.
  • Comparable HA concentration to Profhilo (64 mg/2 ml), often used as a more cost-effective alternative.
  • Non-animal, stabilised HA formulation, manufactured in South Korea under cosmetic/medical quality standards.

Indications

  • Skin remodelling and treatment of skin laxity in the face, particularly the malar and submalar areas.
  • Full-face skin booster treatment to improve hydration, elasticity and overall tissue quality.
  • Dehydrated or dull skin lacking radiance and flexibility.
  • Fine lines and superficial wrinkles, including early periorbital and perioral lines (when injected appropriately).
  • General age-related loss of firmness and mild volume in superficial tissues where a biostimulating skin booster is preferred over a traditional filler.
  • Complementary treatment in protocols combining skin boosters with dermal fillers, toxins or other aesthetic modalities.
  • Patients seeking a Profhilo-like biorevitalising treatment using a high-HA-content hybrid skin booster.

Composition

  • Total hyaluronic acid 64 mg per 2 ml (3.2% w/v), consisting of:
  • 32 mg high molecular weight hyaluronic acid (H-HA) per 2 ml.
  • 32 mg low molecular weight hyaluronic acid (L-HA) per 2 ml.
  • Hyaluronic acid in stabilised, fragmented form designed for gradual release and multi-layer hydration.
  • Non-animal-origin sodium hyaluronate produced by bacterial fermentation.
  • Formulation reported as BDDE-free (no chemical crosslinking agent), functioning as a hybrid, stabilised HA complex.
  • Physiological carrier solution (buffered aqueous solution) suitable for injectable use in the superficial dermis.

Formulation

  • Hybrid, stabilised, non-BDDE hyaluronic acid skin booster combining high and low molecular weight HA.
  • Total HA concentration 64 mg in a 2 ml prefilled syringe (3.2% w/v).
  • Sterile, pyrogen-free injectable solution intended for mesotherapy/skin booster injection in the superficial dermis.
  • Fragmented HA structure for progressive release and extended biorevitalising effect.
  • Single-use 2 ml glass syringe with luer-lock connection (needles typically not supplied in the box).

Packaging

  • Box containing 1 x 2 ml prefilled glass syringe of Revs PRO32.
  • Needles not included (most distributors recommend 25G needles for BAP/5-point technique).
  • Sterile blister packaging for the syringe.
  • Outer carton printed with product name (Revs PRO32), volume (2 ml), HA concentration details, batch number and expiry date.
  • Package insert with basic product information and key usage guidance (varies by market and distributor).

Usage

  • Professional-use only: Revs PRO32 must be administered exclusively by suitably trained and qualified medical or aesthetic practitioners familiar with injectable skin boosters and facial anatomy.
  • Obtain full medical history, including allergies (especially to hyaluronic acid), autoimmune conditions, coagulation disorders, medications and previous aesthetic treatments; obtain informed consent.
  • Inspect outer carton, blister and syringe prior to use; do not use if damaged, opened, expired or if the solution is discoloured or contains particulates.
  • Maintain strict aseptic technique: thoroughly cleanse and disinfect the treatment area and use sterile gloves and equipment.
  • For facial skin laxity and remodelling, Revs PRO32 is commonly injected using a 5-point/BAP-style protocol on each side of the face, with approximately 0.2 ml per injection point (typical 2 ml full-face treatment).
  • Recommended injection depth is generally the superficial subcutaneous/superficial dermal layer depending on local guidance; avoid intravascular injection and overly superficial placement that may cause visible irregularities.
  • Inject slowly with minimal pressure; aspirate where clinically appropriate and follow standard safety precautions to reduce risk of vascular compromise.
  • treatments are often performed as a course of two sessions spaced about 4 weeks apart, with maintenance sessions approximately every 6–9 months depending on clinical outcome and patient factors.
  • After injection, gently massage or mould the area only if required to distribute the product evenly; avoid aggressive manipulation.
  • Dispose of any remaining product and used syringes/needles as clinical sharps waste; Revs PRO32 is single-use and must not be reused or resterilised.
  • Post-treatment advice typically includes avoiding makeup on treated areas for ~12 hours and avoiding intense heat exposure (sauna, sunbeds, very hot showers), vigorous exercise and alcohol for 24–48 hours.
  • Advise patients not to press or massage the treated zones (unless specifically instructed), to sleep on their back where possible on the first night, and to use broad-spectrum sunscreen daily.
  • Instruct patients to contact the clinic immediately if they experience intense pain, blanching or mottling of the skin, marked swelling, visual disturbances, or any signs of infection (redness, warmth, fever, discharge).

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid or any component of the product.
  • History of severe allergic reactions or anaphylaxis to injectable products.
  • Active skin infections, inflammation, dermatitis, acne flare or herpetic lesions at or near the intended injection site.
  • Presence of significant scarring disorders such as a strong tendency to form hypertrophic scars or keloids in the treatment area.
  • Pregnancy or breastfeeding (use is not recommended due to lack of safety data).
  • Patients under 18 years of age.
  • Severe systemic diseases or uncontrolled autoimmune or immunologic conditions unless carefully assessed and deemed appropriate by the treating physician.
  • Significant coagulation disorders or ongoing high-dose anticoagulant therapy without individual risk–benefit assessment.
  • Recent aggressive skin treatments (e.g., deep chemical peels, ablative lasers, dermabrasion) in the intended treatment area until fully healed.
  • Injection into blood vessels or use in areas with compromised vascularity or previous ischemic events is strictly contraindicated.

Adverse Effects

  • Typical transient injection site reactions such as redness, swelling, tenderness, warmth, itching or bruising.
  • Temporary lumps, papules or irregularities at injection points, usually resolving spontaneously or with gentle massage.
  • Mild pain or discomfort during and shortly after injection.
  • Small hematomas or pinpoint bleeding at needle entry sites.
  • Transient changes in sensation (numbness, tingling) related to needle trauma or local tissue response.
  • Delayed inflammatory reactions or hypersensitivity responses including redness, swelling or induration (uncommon).
  • Infection at injection sites, potentially leading to cellulitis or abscess formation if aseptic technique or aftercare is inadequate (rare).
  • Nodules, granuloma-like reactions or persistent induration requiring medical evaluation (rare).
  • Vascular complications if inadvertent intravascular injection or compression occurs, potentially causing blanching, severe pain, tissue ischemia or necrosis; although risk is reduced with superficial techniques, it remains a serious potential adverse event.
  • Very rare but serious events associated with any injectable HA such as visual disturbance or blindness in the event of embolisation; these require immediate emergency management.

Storage Conditions

  • Store in a cool, dry place between approximately 2°C and 25°C (do not freeze).
  • Keep the syringe in its original blister and outer carton to protect from light and contamination until use.
  • Do not use if the product has been frozen, overheated or stored outside the recommended temperature range.
  • Do not use after the expiry date printed on the packaging.
  • Keep out of the sight and reach of children.

Duration

Results generally become visible from the first treatment session and typically last around 6\u20139 months, with some sources indicating longevity up to approximately 12 months depending on skin type, age, lifestyle and treatment protocol.

Onset

Hydration and plumping effects are usually noticeable shortly after treatment, with progressive improvement in tissue quality, firmness and radiance over the following days and weeks as biorevitalisation and collagen stimulation occur.

Browse more Skin Booster

Top Treatments

Top Cities in the UK